tbuckley/cabot-search huggingface dataset:
Immunoelectrophoretic Characteristics of Normal Mouse Serums as a Basis for Studying Pathological Changes in Serums of Mice Carrying Transplantable Malignant Growths&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: J HEREMANS, J CLAUSEN, M T HEREMANS, R RASK-NIELSEN
Journal: JNCI Journal of the National Cancer Institute (1959)

Journal Article Immunoelectrophoretic Characteristics of Normal Mouse Serums as a Basis for Studying Pathological Changes in Serums of Mice Carrying Transplantable Malignant Growths Get access J. Heremans, J. Heremans The Hematological Laboratory, Medical Department A (Head: Professor P. Lambin, M.D.), University of Louvain, Louvain, Belgium, and The University Institute of Biochemistry (Head: Professor R. Ege, Ph.D.), Copenhagen, Denmark Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Clausen, J. Clausen The Hematological Laboratory, Medical Department A (Head: Professor P. Lambin, M.D.), University of Louvain, Louvain, Belgium, and The University Institute of Biochemistry (Head: Professor R. Ege, Ph.D.), Copenhagen, Denmark Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Th. Heremans, M. Th. Heremans The Hematological Laboratory, Medical Department A (Head: Professor P. Lambin, M.D.), University of Louvain, Louvain, Belgium, and The University Institute of Biochemistry (Head: Professor R. Ege, Ph.D.), Copenhagen, Denmark Search for other works by this author on: Oxford Academic PubMed Google Scholar R. Rask-Nielsen R. Rask-Nielsen The Hematological Laboratory, Medical Department A (Head: Professor P. Lambin, M.D.), University of Louvain, Louvain, Belgium, and The University Institute of Biochemistry (Head: Professor R. Ege, Ph.D.), Copenhagen, Denmark Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 22, Issue 1, January 1959, Pages 45–55, https://doi.org/10.1093/jnci/22.1.45 Published: 01 January 1959 Article history Received: 09 June 1958 Published: 01 January 1959
Reye's syndrome and salicylates
Authors: Joseph M. White
Journal: JAMA (1987)

<h3>To the Editor.—</h3> The accusations against the federal regulatory authorities and the pharmaceutical industry contained in the editorial by Dr Mortimer<sup>1</sup>entitled "Reye's Syndrome, Salicylates, Epidemiology, and Public Health Policy" are inconsistent with the facts. The editorial is unfair not only to the Food and Drug Administration (FDA) and the industry, but to the many physicians and scientists who in 1982 and 1983 recognized the serious flaws in the early Reye's syndrome surveys and who advocated that public health decisions be based on sound scientific studies. Dr Mortimer states that "the first reasonably conclusive evidence of an association and a tentative warning appeared in 1980, but no definitive action was taken until 1986." He is wrong on both counts. The evidence in 1980 was far from conclusive. Nearly all public interest and academic commentators at the time, including the American Medical Association (AMA) and the American Academy of Pediatrics,
QOS-41NEURAL NETWORK DISTURBANCES IN CHILDREN TREATED FOR BRAIN TUMOURS
Authors: Samantha Gauvreau, Colleen Dockstader, Diana Harasym, Janine Piscione, Suzanne Laughlin, Brian Timmons, Ute Bartels, Jovanka Skocic, Cynthia de Medeiros, Katrin Scheinemann, Eric Bouffet, Sam Doesburg, Donald Mabbott
Journal: Neuro-Oncology (2016)
Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with <i>EGFR</i>-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.
Authors: Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Wu-Chou Su, Myung-Ju Ahn, Dae Ho Lee, Johan F. Vansteenkiste, Li Zhang, Enriqueta Felip, Bin Peng, Ying Gong, Sylvia Zhao, Taro Amagasaki, Mikhail Akimov, Daniel Shao-Weng Tan
Journal: Journal of Clinical Oncology (2014)

8017 Background: Despite high response rates to EGFR tyrosine kinase inhibitors (TKIs), most patients (pts) with EGFR-mut NSCLC ultimately relapse. Dysregulation of the MET pathway is implicated as a therapeutically tractable resistance mechanism, occurring in 15–20% of cases. INC280 is a highly selective, oral MET inhibitor with preclinical activity in EGFR-mut/MET-activated NSCLC when combined with EGFR TKIs. Methods: This Ph Ib/II, open-label, dose-escalation study of INC280 plus gef was performed in pts (age ≥18 yrs, ECOG PS ≤2) with EGFR-mut NSCLC who progressed after prior EGFR TKI, and have confirmed MET dysregulation (amplification [FISH ≥5 CN] or overexpression [IHC 2/3+]). The primary objective (Ph Ib) was to determine the MTD/recommended Ph II dose (RP2D) of INC280 plus gef; secondary objectives were safety, efficacy, pharmacodynamics and PK. An adaptive Bayesian logistic regression model with overdose control guided dose escalation to establish the MTD. Results: As of December 2, 2013, 41 pts were enrolled in the ongoing Ph Ib part of the study (59% female, median age 58 years). Pts were treated with INC280 at 7 dose cohorts of 100–800 mg QD and 200–600 mg BID, in combination with gef 250 mg QD. Dose-limiting toxicities (DLTs) occurred in 2 pts: dizziness (800 mg QD) and dyspnea (600 mg BID). The most frequent drug-related AEs (any grade [Gr]) were nausea (27 %), vomiting, diarrhea, and rash (all 22%). The most common drug-related Gr 3/4 AEs were increased lipase (7 %), and increased amylase (5%). For one death, causality to INC280 was not ruled out. INC280 exposure increased with dose from 100–800 mg QD and 200–400 mg BID; preliminary data show no PK interactions with gef. Partial responses were seen in 6/41 (15%) evaluable pts; 5 confirmed, 1 unconfirmed, including 3/7 pts (43%) on 400 mg BID; 5/6 responders had EGFR TKIs as a last treatment prior to study entry. All responders had high MET status. Conclusions: Oral INC280 in combination with gef is well tolerated; the RP2D has not yet been defined. Preliminary clinical activity supports further evaluation of INC280 combined with gef in MET-positive NSCLC resistant to EGFR TKIs. Clinical trial identifier: NCT01610336. Clinical trial information: NCT01610336.
Spread of an MRSA clone with heteroresistance to oxacillin in the Netherlands
Authors: W J B Wannet
Journal: Eurosurveillance (2002)

Since 2001, an increase in the number of MRSA strains with heteroresistance to oxacillin has been observed in the Netherlands. These strains can spread unnoticed, as their phenotypic heterogenous resistance to beta-lactams affects the results of susceptibility testing. Therefore, further testing using PBP2a latex agglutination or PCR are recommended.
Hormone stimulation and chemotherapy for breast cancer.
Authors: M E Lippman
Journal: Journal of Clinical Oncology (1987)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1987.5.3.331 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3546610 Hormone stimulation and chemotherapy for breast cancer. M E LippmanxM E LippmanSearch for articles by this author https://doi.org/10.1200/JCO.1987.5.3.331 PDF "Hormone stimulation and chemotherapy for breast cancer.." Journal of Clinical Oncology, 5(3), pp. 331–332© 1987 by American Society of Clinical Oncology
Woyzeck
Authors: Iain McClure
Journal: BMJ (2008)

Georg Buchner (1813-37) packed what most would regard as several lifetimes’ worth of experience into his tragically short 23 years. At the time of his death from typhus in 1837, he had written an incendiary revolutionary pamphlet; a dissertation On Cranial Nerves, which led to his appointment as lecturer in comparative anatomy at Zurich; and two of the greatest plays ever written. The first of these, Danton’s Death (1835) was written in five weeks, during Buchner’s flight into Switzerland from probable imprisonment. It is a gripping political drama, its insight into political intrigue being comparable to Shakespeare. The second play, Woyzeck, though probably unfinished at Buchner’s death, has been responsible for most of the key developments in Western theatre since 1913, when it was first performed in Munich. Quite simply, without Woyzeck, there would be no Brecht and no Beckett.

The play was directly based on the miserable life of Johan Christian Woyzeck, who was beheaded in Leipzig in 1824 for the murder of his mistress in a fit of jealous rage. At the time, Woyzeck’s case made legal history because the accused had been subjected to lengthy medical examination in order to establish if his sentence could be reduced due to diminished responsibility. Buchner stuck to most of the factual detail of his protagonist’s life, telling the story of a poor man’s descent into failure and of his brutal romantic loss that ironically echoes Goethe’s Faust.

Although short as a play, Woyzeck is endlessly innovative and exciting on many levels. From the medical perspective, it delivers a scabrous attack on the ethical pitfalls of clinical research, namely the danger of the doctor playing God. One of the play’s main characters is that of the unnamed doctor who is paying Woyzeck to be a guinea pig for his scientific inquiries. At the time of the play’s action, the doctor has been feeding our hapless hero with nothing but a diet of peas and is monitoring the physiological and psychiatric results daily. It is the doctor’s total lack of interest in the wellbeing of his subject that is dramatic here and the consequence of his (effectively) chemical intervention on our protagonist’s mental state is Woyzeck’s impassioned murder of his beloved, Marie.

What is extraordinary about Woyzeck is how a medical student (who was actively engaged in neurological research at the time of writing his play) had the depth of vision and perception to connect his emerging scientific knowledge with a level of compassion and understanding of human nature that seems beyond his 23 years.
Prevention of Hepatitis B reactivation in the setting of immunosuppression
Authors: Venessa Pattullo
Journal: Clinical and Molecular Hepatology (2016)

Advances in the treatment of malignant and inflammatory diseases have developed over time, with increasing use of chemotherapeutic and immunosuppressive agents of a range of drug classes with varying mechanism and potency in their effects on the immune system. These advances have been met with the challenge of increased risk of hepatitis B virus (HBV) reactivation in susceptible individuals. The magnitude of risk of HBV reactivation is associated with the individual's HBV serological status and the potency and duration of immunosuppression. Individuals with chronic hepatitis B (CHB) and previously infected but serologically cleared HBV infection are both susceptible to HBV reactivation. HBV reactivation in the setting of immunosuppression is a potentially life threatening condition leading to liver failure and death in extreme cases. It is important to recognize that HBV reactivation in the setting of immunosuppression is potentially preventable. Therefore, identification of patients at risk of HBV reactivation and institution of prophylactic antiviral therapy prior to initiation of immunosuppression is essential.
MB-20WDR5 ORCHESTRATES CANCER CELL SELF RENEWAL IN Myc DRIVEN MEDULLOBLASTOMA
Authors: Swati Ghosh, Sujatha Venkataraman, Diane Birks, Nicholas Foreman, Rajeev Vibhakar
Journal: Neuro-Oncology (2016)

MB-20. WDR5 ORCHESTRATES CANCER CELL SELF RENEWAL IN Myc DRIVEN MEDULLOBLASTOMA Swati Ghosh1, Sujatha Venkataraman1, Diane Birks1, Nicholas Foreman1,2, and Rajeev Vibhakar1,2; University of Colorado, Aurora, CO, USA; Children Hospital Colorado, Aurora, CO, USA MYC oncogene driven medulloblastoma (MB) has a poor overall outcome and there is a need for more effective therapies. Wehypothesized that epigenetic mechanisms may mediate MYC-driven medulloblastoma. To address this, we performed a functional epigenome wide RNAi screen targeting 406 epigenetic molecules associated with chromatin remodeling and histone modification in Myc MB cells. Unbiased analysis identified several key regulators of long-term viability in these Myc amplified MB cells. Remarkably we identified multiple proteins that are part of the COMPASS like macromolecular complex as critical mediators of MB cell viability. These include ASH2L, MLL2 (KMT2D), WDR5, DPY30 and HFC1. This complex is critical for methylationof histone3 lysine4 (H3K4me3) andmediating transcriptional activation. We established that WDR5 is important for MYC driven medulloblastoma cell survival. Knock down of WDR5 attenuates clonogenic growth of tumor cells, suppresses stem cell associated gene expression programs and prevents formation of new neurospheres suggesting an inhibition of self-renewal of the medulloblastoma cells. Co-immunoprecipitation studies revealed an interaction between cMYC and WDR5. Confocal microscopy using high cMYC medulloblastoma cells also demonstrated that WDR5 co-localizes with cMYC in nucleus. C-MYC overexpressing neural stem cells differentiate down a neuronal lineage upon WDR5 knockdown. We are now performing more detailed studies on the activity of WDR5 in vitro and in vivo in MYC driven medulloblastoma. Further characterization of WDR5 will provide deeper insight into understanding of group3 medulloblastoma and its therapeutic intervention. Neuro-Oncology 18:iii97–iii122, 2016. doi:10.1093/neuonc/now076.18 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Pharmacotherapy in outpatient psychiatric practice
Authors: M Olfson, H A Pincus, M Sabshin
Journal: American Journal of Psychiatry (1994)

This article examines some of the factors that influence the extent to which psychiatrists provide pharmacotherapy to their outpatients.Data from the 1988-1989 APA Professional Activities Survey are used to define the characteristics of psychiatrists who prescribe medications to a high, medium, and low proportion of their outpatients in treatment. Outpatient assessments, evaluations, or consultations were excluded from this analysis. Correlations between psychiatric practice characteristics and rates of pharmacotherapy are examined.One-third of psychiatrists prescribed medications to less than 46.7% of their outpatients, one-third prescribed medications to between 46.7% and 84.6%, and one-third prescribed medications to over 84.6% of their outpatients. The psychiatrists in the last group included a proportionately higher number of young psychiatrists, men, nonwhites, those without psychoanalytic or child psychiatry training, those with larger caseloads, and those who worked in the public sector. These psychiatrists also treated a disproportionately large number of patients with schizophrenia and related psychotic disorders. In a multivariate model, clinical, practice, and educational variables, but not demographic variables, were found to correlate with the extent of pharmacotherapy provided.Psychiatrists vary widely in the extent to which they are involved in prescribing psychotropic medications. The diagnostic composition of their caseload, their work setting, and their educational background, but not their demographic characteristics, appear to influence the extent of their involvement.
Successful T-cell reconstitution after unrelated cord blood transplantation in a patient with complete DiGeorge syndrome
Authors: Daiei Kojima, Hideki Muramatsu, Yusuke Okuno, Shinsuke Kataoka, Norihiro Murakami, Yoshihiro Tanahashi, Kyogo Suzuki, Tamaki Kato, Yuko Sekiya, Nozomu Kawashima, Atsushi Narita, Nobuhiro Nishio, Asahito Hama, Kohsuke Imai, Shigeaki Nonoyama, Yoshiyuki Takahashi, Seiji Kojima
Journal: Journal of Allergy and Clinical Immunology (2016)
A case of secondary amyloidosis with calcium deposition in the liver.
Authors: NOBUYOSHI FUKUMITSU, YUTAKA MORI, DAISUKE TSUCHIDA, MAYUKI UCHIYAMA, YUTAKA YAMAGUCHI
Journal: Clinical Nuclear Medicine (2001)

FUKUMITSU, NOBUYOSHI M.D.; MORI, YUTAKA M.D.; TSUCHIDA, DAISUKE M.D.; UCHIYAMA, MAYUKI M.D.; YAMAGUCHI, YUTAKA M.D. Author Information
Cell Volume, Plasma Volume and Cell Percentage in Splanchnic Circulation of Splenectomized Dogs
Authors: SHU CHIEN
Journal: Circulation Research (1963)

The circulating splanchnic cell and plasma volumes were measured with the regional dilution technique in splenectomized dogs under sodium pentobarbital. For a 10-kg dog, the average circulating splanchnic cell volume is 56 (SE m = 5.0) ml and the average circulating splanchnic plasma volume is 98 (SE m = 7.2) ml. These values represent 20% of the total plasma volume respectively. The splanchnic cell percentage, averaging 36.3% (SE m = 1.32%), is significantly lower than the large vessel cell percentage (average 42.4%) and is almost equal to the overall cell percentage. The splanehnic F cells value averages 0.86 and is almost the same as the overall F cells value. Therefore, the splanchnic circulation contains a portion of the total "extra plasma" in proportion to the blood volume in this region. The splanchnic mean circulation time of the plasma (average 42 seconds) is significantly longer than that of the cells (average 33 seconds).
Out of the courtroom and into the clinic.
Authors: N E Davidson
Journal: Journal of Clinical Oncology (1992)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1992.10.4.517 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 1548515 Out of the courtroom and into the clinic. N E DavidsonxN E DavidsonSearch for articles by this author https://doi.org/10.1200/JCO.1992.10.4.517 First Page PDF © 1992 by American Society of Clinical Oncology
Coexistence and Impact of Limb Muscle and Diaphragm Weakness at Time of Liberation from Mechanical Ventilation in Medical Intensive Care Unit Patients
Authors: Martin Dres, Bruno-Pierre Dubé, Julien Mayaux, Julie Delemazure, Danielle Reuter, Laurent Brochard, Thomas Similowski, Alexandre Demoule
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Intensive care unit (ICU)- and mechanical ventilation (MV)-acquired limb muscle and diaphragm dysfunction may both be associated with longer length of stay and worse outcome. Whether they are two aspects of the same entity or have a different prevalence and prognostic impact remains unclear.To quantify the prevalence and coexistence of these two forms of ICU-acquired weakness and their impact on outcome.In patients undergoing a first spontaneous breathing trial after at least 24 hours of MV, diaphragm dysfunction was evaluated using twitch tracheal pressure in response to bilateral anterior magnetic phrenic nerve stimulation (a pressure <11 cm H2O defined dysfunction) and ultrasonography (thickening fraction [TFdi] and excursion). Limb muscle weakness was defined as a Medical Research Council (MRC) score less than 48.Seventy-six patients were assessed at their first spontaneous breathing trial: 63% had diaphragm dysfunction, 34% had limb muscle weakness, and 21% had both. There was a significant but weak correlation between MRC score and twitch pressure (ρ = 0.26; P = 0.03) and TFdi (ρ = 0.28; P = 0.01), respectively. Low twitch pressure (odds ratio, 0.60; 95% confidence interval, 0.45-0.79; P < 0.001) and TFdi (odds ratio, 0.84; 95% confidence interval, 0.76-0.92; P < 0.001) were independently associated with weaning failure, but the MRC score was not. Diaphragm dysfunction was associated with higher ICU and hospital mortality, and limb muscle weakness was associated with longer duration of MV and hospital stay.Diaphragm dysfunction is twice as frequent as limb muscle weakness and has a direct negative impact on weaning outcome. The two types of muscle weakness have only limited overlap.
Chemotherapy for colorectal carcinoma: one small step forward, one step backward.
Authors: N Kemeny
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.6.1287 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7751905 Chemotherapy for colorectal carcinoma: one small step forward, one step backward. N KemenyxN KemenySearch for articles by this author https://doi.org/10.1200/JCO.1995.13.6.1287 First Page PDF © 1995 by American Society of Clinical Oncology
LG-24BRAF ALTERATIONS IN PEDIATRIC PILOCYTIC ASTROCYTOMAS WITH RECURRENCES/PROGRESSION
Authors: Amulya Nageswara Rao, Mira Kohorst, Deepti Warad, Keith Ligon, David Daniels, Aditya Raghunathan, Claire Sinai, Azra Ligon, Caterina Giannini
Journal: Neuro-Oncology (2016)
Abstract LB-235: Therapeutic human papillomavirus vaccine design based on epitopes identified on the tumor cell surface by mass spectrometry
Authors: Stephanie Hoppe, Renata Blatnik, Julia P. Schessner, Lisa Dressler, Alina Steinbach, Jan Winter, Martin Wuehl, Alexandra Klevenz, Hadeel Khallouf, Angelika B. Riemer
Journal: Cancer Research (2015)

Abstract Detailed knowledge about T cell epitopes, which are bona fide presented on the surface of human papillomavirus (HPV)-transformed cells, is essential for rational design of therapeutic HPV vaccines. HPV affects the cellular antigen processing machinery, thus not every epitope derived from viral proteins is presented on human leukocyte antigen (HLA) molecules. Even the presented epitopes are displayed in low abundance. In this study, we developed a highly sensitive nano-UPLC-ESI-MS3 multiple-reaction monitoring mass spectrometry (MS) approach for direct detection of low-abundant epitopes on the cell surface. Several web-based prediction algorithms were used to predict prospective epitopes from the HPV16 E6 and E7 proteins. These candidate epitopes were tested for actual HLA binding in cellular binding assays. The presence of binding peptides on HPV16-transformed cells was analyzed by our MS technology. Immunogenicity of candidate peptides was assessed in vitro with short-term and long-term T cell line experiments, generated from peripheral blood mononuclear cells of healthy donors, and in vivo for a selected HLA-A2-restricted epitope in HLA-A2/DR-1 transgenic mice. To ensure &amp;gt;95% population coverage, prospective HPV epitopes were predicted for the HLA supertypes HLA-A1, A2, A3, A11, A24, B7, and B15. Close to 500 peptides were tested in competition-based binding assays and multiple novel binders were identified. MS epitope detection was first established for HLA-A2 epitopes, and is now extended to the other supertypes. In the immunogenicity assays, several peptides induced robust IFN-γ responses. In conclusion, several new HPV16 E6 and E7 epitopes were identified and validated in this study. They represent promising candidates for inclusion into a therapeutic HPV vaccine. Validated epitopes are the basis of rational therapeutic vaccine design and are also important for immunomonitoring purposes. Citation Format: Stephanie Hoppe, Renata Blatnik, Julia P. Schessner, Lisa Dressler, Alina Steinbach, Jan Winter, Martin Wuehl, Alexandra Klevenz, Hadeel Khallouf, Angelika B. Riemer. Therapeutic human papillomavirus vaccine design based on epitopes identified on the tumor cell surface by mass spectrometry. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-235. doi:10.1158/1538-7445.AM2015-LB-235